Global Uveitis Drugs Market to Grow by USD 452.87 Million During 2019-2023 | Technavio

LONDON–(BUSINESS WIRE)–#Biotechnology–Technavio’s latest market research report on the global uveitis drugs
market predicts the market to witness a CAGR of close to 7% during the
forecast period. This research report segments the market by product
(small molecules and biologics) and geography (North America, Europe,
Asia, and ROW).

Increasing popularity of combination therapies to gain popularity

Combination therapies are often being administered separately as a
fixed-dose combination or as a single-dose formulation with two or more
active ingredients. The adoption of combination therapies has increased
considerably in the recent years due to advantages including cost
reduction and higher effectiveness of two active pharmaceutical
ingredients being administered at the same time. Therefore, companies
are increasingly focusing on the development and marketing of
combination therapies for the treatment of uveitis. With the growing
adoption of combination therapies for treatment of this eye condition
with multifactorial etiologies, the global
uveitis drugs market is anticipated to witness a surge in growth
during the next few years.

Small molecules segment will garner the highest share

The small molecules segment is expected to garner the highest uveitis
drugs market share mainly due to the increased use of corticosteroids
for the treatment of uveitis. Small molecules are synthesized by
chemical reactions between different organic or inorganic compounds. The
growth of the small molecules segment is mainly driven by the easy
availability and economical cost of corticosteroid generics. Many
generics including prednisone, methotrexate, and others are available in
the market for treating uveitis. The use of corticosteroids as the first
line of therapy for treating non-infectious ocular inflammatory diseases
has increased as these drugs are inexpensive, potent, and provide quick
relief.

“The growth of the small molecules segment will be driven by recent
product approvals and expected approvals. Vendors have received US FDA
approval for the treatment of chronic non-infectious uveitis. In
addition, topical corticosteroids are largely being used for the
treatment of anterior uveitis. Therefore, rising adoption of small
molecules for the treatment of chronic uveitis will boost the market
during the forecast period.” says a senior research analyst at Technavio

Looking for more information on this market? Request
a free sample report

Uveitis drugs to witness fastest adoption in Asia

Asia is expected to witness the fastest uveitis drugs market growth
during the forecast period owing to the high prevalence of uveitis in
the region. Various governments and private organizations have been
taking initiatives to increase the awareness of the disease and offer
several treatment options for patients in the region. In addition, the
market offers significant growth prospects owing to the presence of
advanced economies such as Japan. Furthermore, the market in India and
China is also expected to record significant market growth in the coming
years owing to the rise in disposable incomes.

Technavio’s sample reports are free of charge and contain multiple
sections of the report such as the market size and forecast, drivers,
challenges, trends, and more.

Some of the key topics covered in the global
uveitis drugs market analysis include:

Market Landscape

• Market ecosystem
• Market characteristics
• Market segmentation analysis

Market Sizing

• Market definition
• Market size and forecast

Five Forces Analysis

Market Segmentation

Geographical Segmentation

• Regional comparison
• Key leading countries

Market Drivers

Market Challenges

Market Trends

Vendor Landscape

• Vendors covered
• Vendor classification
• Market positioning of vendors
• Competitive scenario

About Technavio

Technavio
is a leading global technology research and advisory company. It
provides detailed market research reports that provide clients with
actionable insights to help them identify market opportunities and
design effective strategies to optimize their market position.

With over 500 specialized analysts, Technavio boasts of an extensive
report library comprising of over 10,000 reports, covering 800
technologies, spanning across 50 countries. Their client base consists
of enterprises of all sizes, including more than a hundred Fortune 500
companies. This growing client base relies on Technavio’s comprehensive
coverage, extensive research, and actionable market insights to identify
opportunities in existing and potential markets. Technavio helps
companies to assess their competitive position within changing market
scenarios.

If you are interested in more information, please contact our media team
at [email protected].

Contacts

Technavio Research
Jesse Maida
Media & Marketing Executive
US:
+1 844 364 1100
UK: +44 203 893 3200
www.technavio.com